Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Genzyme Will Build A New Enzyme Plant
by Michael McCoy
January 24, 2011
| A version of this story appeared in
Volume 89, Issue 4
Genzyme will spend some $335 million to build a manufacturing plant at its Geel, Belgium, site for alglucosidase alfa, the active ingredient in an enzyme replacement therapy that FDA approved last year for Pompe disease. The plant will include two 4,000-L bioreactors, bringing the number of bioreactors dedicated to the enzyme to five. About 150 jobs will be added to the 450 positions already at the site. Last year, Genzyme paid the U.S. government a $175 million fine because of problems at its enzyme plant in Allston, Mass.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter